In summary, the results from HGSOC patients verified the high co-expression of TIM-3 and PD-1 and efficacy of their co-blockades in enhancing the anti-tumor immunity of CD8+TILs and CD11c+ myeloid cells. This evidence concerns the gene PDCD1 and neoplasm.